NeurAxis, Inc.

Contributing Author

Recent Articles by NeurAxis, Inc.

May-21	NeurAxis Announces $5.0 Million Registered Direct Offering NRXS -19.80% GlobeNewswire
May-20	NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms NRXS GlobeNewswire
May-12	NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues NRXS GlobeNewswire
May-05	NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 NRXS GlobeNewswire